Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Farr

Pediatrics Birmingham, AL Medical Doctor

NPI 1982792776 CMS profile 271489

806 St Vincents Dr, Ste 615, Birmingham, AL 35205

Open in the dashboard

General payments

$1,611

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Farr of Birmingham, AL is reported in the CMS Open Payments database as having received $1,611 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $279 14
2024 General $293 16
2023 General $236 13
2022 General $156 10
2021 General $88 7
2020 General $293 9
2019 General $266 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Farr
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Patrick Farr were reported at $279. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Patrick Farr Pediatrics median Middle half National median
2019 $266 $86 $31–$183 $163
2020 $293 $49 $22–$110 $114
2021 $88 $68 $27–$158 $132
2022 $156 $77 $30–$173 $149
2023 $236 $88 $33–$190 $160
2024 $293 $94 $34–$206 $164
2025 $279 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corium, Inc. $319 18 payments
  2. GlaxoSmithKline, LLC. $287 19 payments
  3. Pfizer Inc. $217 10 payments
  4. Welch Allyn $162 1 payment
  5. Ironshore Pharmaceuticals Inc. $151 7 payments
  6. Merck Sharp & Dohme Corporation $95 6 payments
  7. Supernus Pharmaceuticals, Inc. $88 5 payments
  8. Teva Pharmaceuticals USA, Inc. $75 6 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $44 2 payments
  10. Sobi, Inc $43 2 payments
  11. Other $130 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,421 82 payments
  2. Gift $162 1 payment
  3. Education $28 1 payment
Products named General payments · program years 2019–2025
  1. Azstarys $319 18 payments
  2. BEXSERO $287 19 payments
  3. PREVNAR 20 $163 7 payments
  4. Spot Vision Screener $162 1 payment
  5. Jornay PM 20mg capsules (Bottle of 100) $134 6 payments
  6. Qelbree $88 5 payments
  7. PENBRAYA $68 3 payments
  8. GARDASIL 9 $67 4 payments
  9. VAXNEUVANCE $55 3 payments
  10. PREVNAR 13 $54 3 payments
  11. Other $642 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record